Granulocyte Transfusions in Pediatric Hemato‐Oncology: Neutrophil Response and CRP Kinetics
Pediatric Blood & Cancer · 2025-11 · 72 (11)
DOI: 10.1002/pbc.31979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 11.08.2025. Verfasst von Aviv Sever und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology/Oncology, Schneider Children's Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: C-Reactive Protein, Neutrophils, Neutropenia, Leukocyte Transfusion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Granulocyte transfusions (GTXs) are used in neutropenic pediatric hemato‐oncology patients with infections unresponsive to antimicrobial therapy, but their clinical benefit remains uncertain.
Methods
We retrospectively reviewed all pediatric patients who received GTXs between 2013 and 2023 at a tertiary medical center. We assessed associations between GTX administration, absolute neutrophil count (ANC) increment, and C‐reactive protein (CRP) reduction as a surrogate marker of treatment response.
Results
Forty‐nine patients received 312 GTXs across 56 episodes: 47 for therapeutic use during active infection and nine for secondary prophylaxis. Higher ANC increments were observed after transfusions containing ≥0.6 × 10⁹ neutrophils/kg from same‐day collections. ANC rises were transient, typically declining within 24 hours. CRP levels decreased significantly after the first GTX ( p = 0.001) and more markedly by the end of treatment ( p < 0.001). ANC increment was significantly associated with CRP reduction ( p = 0.006). GTX‐related adverse events occurred in 3% of transfusions. Infection‐related mortality was 17% in the treatment group, while no severe infections occurred in the secondary prophylaxis group.
Conclusions
GTXs appear to be a safe adjunctive therapy in high‐risk neutropenic children with severe infections. The observed correlation between ANC increment and CRP reduction supports a potential therapeutic effect and warrants further prospective evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology/Oncology, Schneider Children's Medical Center, Petah Tikva, Israel.
- Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Blood Services & Apheresis Institute, Rabin Medical Center, Petach Tikva, Israel.
- Bone Marrow Transplant Unit, Schneider Children's Medical Center, Petach Tikva, Israel.
- Pediatric Infectious Disease Unit, Schneider Children's Medical Center, Petah Tikva, Israel.
ORCID-Profile: Aviv Sever, Ron Rabinowicz, Shlomit Barzilai-Birenboim, Assaf Yanir
Zitieren
APA
Sever, A., Rabinowicz, R., Barzilai-Birenboim, S., Fisher, S., Levi, R. G., Yanir, A., Stein, J., Bilavsky, E., Yacobovich, J., & Yahalom, V. (2025). Granulocyte Transfusions in Pediatric Hemato‐Oncology: Neutrophil Response and CRP Kinetics. Pediatric Blood & Cancer, 72(11). https://doi.org/10.1002/pbc.31979
Vancouver
Sever A, Rabinowicz R, Barzilai-Birenboim S, Fisher S, Levi RG, Yanir A, et al. Granulocyte Transfusions in Pediatric Hemato‐Oncology: Neutrophil Response and CRP Kinetics. Pediatric Blood & Cancer. 2025;72(11). doi:10.1002/pbc.31979
BibTeX
@article{Sever2025,
author = {Sever, Aviv and Rabinowicz, Ron and Barzilai-Birenboim, Shlomit and Fisher, Salvador and Levi, Ronit Goldman and Yanir, Assaf and Stein, Jerry and Bilavsky, Efraim and Yacobovich, Joanne and Yahalom, Vered},
title = {Granulocyte Transfusions in Pediatric Hemato‐Oncology: Neutrophil Response and CRP Kinetics},
journal = {Pediatric Blood & Cancer},
year = {2025},
volume = {72},
number = {11},
doi = {10.1002/pbc.31979}
}
EUVIMED